Logo
x

Search

Subscribe Now

tris pharma

Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain

Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain

  • January 23, 2025
Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain

Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain

  • August 22, 2024
Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

  • May 30, 2024
Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder

Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder

  • August 17, 2022
Insights+: The US FDA New Drug Approvals in November 2021

Insights+: The US FDA New Drug Approvals in November 2021

  • December 16, 2021
Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

Tris Pharma’s Dyanavel XR (amphetamine) Receives US FDA’s Approval for the Treatment of ADHD

  • November 5, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.